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Abstract
Objective: Metformin has had a 'black box' contraindication in diabetic patients with heart failure
(HF), but many believe it to be the treatment of choice in this setting. Therefore, we attempted to
conduct a pilot study to evaluate the feasibility of undertaking a large randomized controlled trial
with clinical endpoints.
Study Design: The pilot study was a randomized double blinded placebo controlled trial. Patients
with HF and type 2 diabetes were screened in hospitals and HF clinics in Edmonton, Alberta,
Canada (population ~1 million). Major exclusion criteria included the current use of insulin or high
dose metformin, decreased renal function, or a glycosylated hemoglobin <7%. Patients were to be
randomized to 1500 mg of metformin daily or matching placebo and followed for 6 months for a
variety of functional outcomes, as well as clinical events.
Results: Fifty-eight patients were screened over a six month period and all were excluded.
Because of futility with respect to enrollment, the pilot study was abandoned. The mean age of
screened patients was 77 (SD 9) years and 57% were male. The main reasons for exclusion were:
use of insulin therapy (n = 23; 40%), glycosylated hemoglobin <7% (n = 17; 29%) and current use
of high dose metformin (n = 12; 21%). Overall, contraindicated metformin therapy was the most
commonly prescribed oral antihyperglycemic agent (n = 27; 51%). On average, patients were
receiving 1,706 mg (SD 488 mg) of metformin daily and 12 (44%) used only metformin.
Conclusion: Despite uncertainty in the scientific literature, there does not appear to be clinical
uncertainty with regards to the safety or effectiveness of metformin in HF making a definitive
randomized trial virtually impossible.
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Background
Metformin has been approved for use in the treatment of
type 2 diabetes mellitus for nearly 3 decades in Europe
and Canada and for a decade in the United States (US).
Numerous studies have shown metformin to be highly
effective and safe in the treatment of type 2 diabetes [1-3].
Metformin is the only antidiabetic agent that has been
shown to reduce mortality in patients newly diagnosed
with type 2 diabetes and the only antidiabetic agent not
shown to be associated with increased morbidity and
mortality in patients with cardiac disease, including heart
failure [2-5].
Despite this, product labeling for metformin in Canada,
the US, and the EU state that it is contraindicated in most
patients with heart failure, although recent changes have
been made in the US [6-8]. Diabetes is a common comor-
bidity in patients with heart failure and portends a partic-
ularly poor prognosis[9,10]. As such, significant
proportion of patients with diabetes may be potentially
denied a beneficial treatment. It is thus not surprising that
there has been a vigorous debate in the literature about
whether or not metformin should be used in patients with
heart failure and type 2 diabetes[4,7,11-24].
Indeed, a recent systematic review and meta-analysis sug-
gests that in patients with comorbid heart failure and dia-
betes, metformin is the only agent which has not been
associated with harm[25]. Importantly, the current evi-
dence supporting metformin's use in heart failure is based
on two population-based epidemiologic studies and both
recommended confirmation of their findings in rand-
omized trials[4,17]. Given the robust debate in the litera-
ture about the role of metformin in heart failure, this
appeared to be a question that needed to be resolved with
a randomized controlled trial[26].
We designed and implemented a pilot study, PHANTOM
(Patients with Heart Failure ANd Type 2 Diabetes Treated
with Placebo Or Metformin), to evaluate the feasibility of
a large randomized controlled trial of metformin in
patients with heart failure and type 2 diabetes (ClinicalTri-
als.gov Identifier: NCT00325910). This paper describes our
experiences in the implementation of the PHANTOM
Pilot study and its implications for other clinical trials.
Methods
Study Design
The PHANTOM pilot study was a multi-centre, prospec-
tive randomized blinded placebo controlled trial
designed to examine functionality, morbidity, and mor-
tality outcomes in patients with heart failure and diabetes
mellitus who are treated with metformin therapy over a 6
month period. Two hospitals, the University of Alberta
Hospital and the Misericordia Hospital, and one outpa-
tient specialized heart failure clinic in Edmonton, Alberta,
Canada (population 1 million) participated in the
study[27]. The University of Alberta Hospital is an 800-
bed tertiary university-based teaching hospital and has
been a recruitment site for many major cardiovascular tri-
als including the Digitalis Investigation Group (DIG)
Trial, the Heart Outcomes Prevention Evaluation (HOPE)
Study, the Studies of Left Ventricular Dysfunction
(SOLVD), the Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary Arter-
ies (GUSTO) trials. The Misericordia Hospital is a 500-bed
community hospital also involved in several large rand-
omized trials in acute coronary syndromes and heart fail-
ure. The study protocol was reviewed and approved by the
Research Ethics Board of all participating sites.
Eligibility
We screened consecutive patients older than 18 years,
admitted to the hospital or emergency room or registered
patients of the local heart failure clinics. Inclusion criteria
were: physician diagnoses of symptomatic heart failure
(NYHA class II, III, IV) and type 2 diabetes (i.e., a previous
physician diagnosis or actively receiving oral antidiabetic
agents or a new diagnosis of type 2 diabetes, defined as a
fasting blood glucose ≥ 7.0 mmol/L or random blood glu-
cose ≥ 11.1 mmol/L, and accompanied by acute metabolic
decompensation or 2 hour plasma glucose in a 75 gram
oral glucose tolerance test ≥ 11.1 mmol/L)[28]. We
excluded patients if they were receiving greater than 1500
mg of metformin daily, were unwilling to change their
antidiabetic regimens, were receiving insulin therapy, had
a serum creatinine ≥ 180 μmol/L, had an A1c < 7.0%, were
unable to communicate because of language barriers, had
dementia or mental illness, were unwilling to complete
self-monitoring of serum blood sugars during the trial
period, were participating in another heart failure or dia-
betes clinical trial involving medications, or had signifi-
cant comorbidities or a terminal illness precluding them
from following the trial protocol over the 6 month follow-
up period.
Screening
Potential patients were identified through referrals of hos-
pitalized or heart failure clinic patients. After identifica-
tion, a two-stage screening process began. In stage 1,
potentially eligible individuals were screened for non-
invasive inclusion/exclusion criteria (i.e., all exclusion cri-
teria except A1c and serum creatinine). In stage 2, patients
who were not excluded after stage 1 were approached for
consent to a blood sample to determine A1c and serum
creatinine eligibility (if not previously completed as part
of their clinic or hospital medical care). Eligible patients
meeting all inclusion and exclusion criteria and consent-
ing to the trial continued with the study protocol.Trials 2009, 10:12 http://www.trialsjournal.com/content/10/1/12
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Randomization and study procedures
Consenting patients were to be randomized to either met-
formin or matching placebo tablets in a 1:1 ratio. Rand-
omization was planned through a secure website
provided by the project office (Epidemiology Coordinat-
ing and Research (EPICORE) Centre, University of
Alberta).
Patients were to be assessed at baseline and six months
later, with monthly telephone contact to assess response
to the study medication and ascertain clinical outcomes.
Follow-up visits and blood testing (A1c and serum creati-
nine) were planned for 3 and 6 month visits. We planned
a dosage titration protocol where patients would be
instructed to slowly titrate their study medication to a
maximum dose of 1500 mg per day over a 3 week period
based on a published titration protocol[1].
Study Endpoints
The primary outcome was a composite endpoint of all-
cause mortality or all-cause hospitalization. As secondary
endpoints, comparisons of mean change in A1c, six
minute walk distance, and mean change in health-related
quality of life (i.e., RAND-12, EQ-5D, and Kansas City
Cardiomyopathy Questionnaire) scores from baseline to
the 6 month follow-up visit were also planned. In addi-
tion, we established criteria for monitoring safety of met-
formin, to identify patients developing lactic acidosis
requiring urgent medical attention, as defined as an emer-
gency room visit or hospitalization.
Sample Size Considerations
We anticipated the full study would require a sample size
of 1000 patients with heart failure and diabetes to detect
an absolute difference in event rates of at least 10% based
on an incidence rate of 50%[29] in our primary outcome
per year with a two-tailed alpha = 0.05 and beta = 0.10.
The goal of the pilot study was to enroll 100 patients.
Results
Recruitment for the study began May 1, 2006. As of Octo-
ber 15th, 2006, fifty-eight consecutive patients with diabe-
tes and heart failure were screened through the outpatient
ambulatory heart failure clinic (n = 8, 14%) and in-patient
cardiology and general medical wards (n = 50, 86%) with
no patients meeting eligibility criteria. Using a conserva-
tive estimate of 1 patient enrolled for every 10 patients
screened, our data suggests that the likelihood that a sig-
nificant number of potentially eligible patients were
missed during screening would be less than 5%. Indeed,
review of the Regional Diabetes Program electronic data-
bases, which at the time contained approximately 500
individuals with type 2 diabetes and heart failure, suggests
very few patients (<1%) would have been potentially eligi-
ble for the trial. This poor availability of suitable patients
led the Steering Committee to recommend that the study
be abandoned.
The characteristics of the individuals screened for the pilot
study are shown in Table 1. Of note, 5 patients refused to
have their screening data collected and are therefore not
included in our results. Of the patients admitted to hospi-
tal (n = 45, 85%), heart failure (n = 22, 49%) was the most
common admitting diagnosis. Acute coronary syndromes
(n = 7, 16%) and diabetes (n = 4 (9%) were the next most
common reasons for admission. The median length of
stay in hospital was 12 days (interquartile range 9 to 36).
Overall, the patients screened represented a typical popu-
lation of patients with heart failure with 57% males and
an average age of 77 (SD 9) years. At the time of screening,
51 (96%) patients were receiving an angiotensin convert-
ing enzyme (ACE) inhibitor or angiotension receptor
blockers (ARB) (Table 1). Approximately two-thirds of
patients were also receiving beta-blockers, antiplatelet and
lipid-lowering therapies with 27 (51%) patients receiving
all three therapies.
The use of insulin (n = 23, 43%) was the most common
reason for trial exclusion (Figure 1). Of the patients receiv-
ing insulin therapy, 11 (48%) had additional exclusion
criteria. Overall, 11 (48%) patients received insulin in
combination with oral antidiabetic agents. The second
most common reason for exclusion from the trial was an
A1c value less than 7%. Of the patients who had an A1c
available (n = 35, 65%), 17 (49%) patients were excluded
with an A1c less than 7% reported in their medical records
(Figure 1). The mean A1c was 7.3% (SD 2) (Table 1). This
may misrepresent the true A1c values, however, as not all
patients had an A1c measured due to the two stage screen-
ing protocol.
Despite being 'absolutely' contraindicated in this popula-
tion during our period of study, metformin was the most
commonly prescribed oral antidiabetic agent with 27
(51%) patients receiving it at the time of screening (Table
1). In comparison, few patients were receiving therapy
with sulfonylureas, thiazolidinediones, meglitinides or
alpha glucosidase inhibitors (Table 1). Although the dura-
tion of therapy with metformin in these patients was not
ascertained, 4 subjects with heart failure were newly initi-
ated on metformin during their hospitalization. Of the
patients receiving metformin, 12 (44%) were receiving
greater than 1500 mg per day and were therefore excluded
from our study (Figure 1). On average, patients were
receiving 1,706 mg per day (SD 488) with 2000 mg per
day as the most common daily dose regimen. Twelve
(44%) patients used metformin as monotherapy, 9 (33%)
in combination with other oral agents and 6 (22%) in
combination with insulin alone. Metformin was alsoTrials 2009, 10:12 http://www.trialsjournal.com/content/10/1/12
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more commonly prescribed in combination with insulin
than other oral agents. Of the 23 patients receiving insulin
therapy, 8 (35%) were also prescribed metformin. We saw
no significant differences between patients receiving met-
formin and non-metformin regimens in terms of clinical
or demographic characteristics (Table 1).
Discussion
A guiding principle for the conduct of a randomized con-
trolled trial is that of equipoise, or perhaps more appro-
priately 'uncertainty' as to whether the therapy under
study works[26]. Although metformin has been demon-
strated to improve outcomes, its use in people with heart
failure and type 2 diabetes is still a contentious issue. Cli-
nicians and researchers have argued both sides of the issue
providing strong evidence for the criterion of uncer-
tainty[4,7,11-24]. Results of our pilot study would sug-
gest, however, that there may be discordance between the
scientific community and practicing clinicians.
Over 50% of patients with diabetes and heart failure in
our pilot study were receiving metformin, either alone or
in combination with other antidiabetic agents, suggesting
there is no uncertainty in the eyes of clinicians. Although
this may be surprising, one must consider that metformin
therapy is one of the most commonly prescribed antidia-
betic agents and has a long history of use in Canada.
Indeed, a recent population based study using Canadian
data suggested that two-thirds of all patients with type 2
diabetes treated with antidiabetic medications receive
metformin therapy, either alone or in combination with
other agents[30]. Furthermore, observational data in Can-
ada, Europe, and the US have shown that 20 to 25% of
patients receiving metformin therapy also have comorbid
heart failure[4,11,17,20,23,31,32] and US data has indi-
cated that the use of metformin has increased by over 50%
in patients with heart failure in recent years[12]. In our
pilot study, half of all subjects were actively receiving met-
formin therapy with the majority of people receiving rela-
tively high doses of metformin therapy (i.e., >1500 mg/
day). Given the accumulated research, including our pilot
data, it would seem there is little uncertainty at the clini-
cian level regarding the use of metformin in patients with
heart failure.
Should there be uncertainty with regards to the use of
metformin in patients with heart failure? Perhaps not,
considering the evidence base for the efficacy of met-
formin in type 2 diabetes. Indeed, numerous observa-
tional and randomized controlled studies have clearly
shown metformin to be highly efficacious for patients
with type 2 diabetes[1-4,17]. Moreover, epidemiological
evidence has suggested that metformin may be associated
with improved outcomes in patients with heart fail-








No. (%) or Mean ± SD
Age – yrs 76.5 ± 8.6 78.2 ± 8.5 74.9 ± 8.7 0.17
Sex – male 30 (57) 16 (62) 14 (52) 0.48
Weight (kg) 82 ± 25 80 ± 22 84 ± 28 0.74
Serum Creatinine (μmol/L) 135 ± 64 147 ± 75 123 ± 49 0.17
Creatinine Clearance (ml/min) 49 ± 23 45 ± 18 53 ± 26 0.19
A1c (%)† 7.3 ± 0.02 6.8 ± 1.2 7.7 ± 2.6 0.22
Heart Failure Medications
Beta-Blockers 38 (72) 18 (69) 20 (74) 0.70
ACE Inhibitors or ARBs 51 (96) 26 (100) 25 (93) 0.49
Calcium Channel Blockers 18 (34) 8 (31) 10 (37) 0.63
Antiplatelet Agents 44 (83) 21 (81) 23 (85) 0.73
Digoxin 9 (17) 4 (15) 5 (19) 1.0
Spironolactone 12 (23) 5 (19) 7 (26) 0.56
Lipid Therapy 41 (77) 19 (73) 22 (82) 0.47
Nitrates 10 (19) 4 (15) 6 (22) 0.73
Diabetes Medications
Insulin 23 (43) 15 (58) 8 (30) 0.039
Sulfonylureas 8 (15) 3 (12) 5 (19) 0.70
Thiazolidinediones 4 (8) 1 (4) 3 (11) 0.61
Meglitinides 2 (4) 1 (4) 1 (4) 1.00
* – five patients refused to have data included
† – 34 people had A1c assessed in previous 3 months; 15 people in non-metformin user and 19 people in metformin user groups
‡ – for comparison between non-metformin and metformin groupTrials 2009, 10:12 http://www.trialsjournal.com/content/10/1/12
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ure[4,17,25]. The potential scientific uncertainty with
using metformin in patients with heart failure seems to be
focused on the risks rather than the possible benefits. One
should note, however that although there are two large
meta-analyses and a case series indicating that the risk of
lactic acidosis with metformin is an extremely rare event
occurring at the same rate as other antidiabetic agents,
uncertainty around its safety suggested that a randomized
controlled trial was warranted. This uncertainty, however,
seems to be waning.
Since the implementation of the pilot study, several fun-
damental changes have occurred surrounding the use of
metformin in both Canada and the United States. In
2007, the United States Food and Drug Administration
removed the heart failure contraindication from the pack-
aging label for metformin therapy (Glucophage® and Glu-
cophage XR®); however, a 'black-box' warning still exists for
the use of metformin in this population suggesting cau-
tion if it is used at all. Similar labeling changes have not
yet occurred in Canada, although the 2008 Canadian Dia-
betes Association clinical practice guidelines have indi-
cated that metformin should be considered as first-line
therapy in patients with heart failure (Grade C, Level 3
[observational evidence])[33].
Our experience should be viewed in light of several other
considerations. The inability to enroll patients into the
pilot study may have been influenced by numerous fac-
tors including the patient-clinician relationship and the
perceived importance of the trial[34]. It is possible, for
example, that admitting the potential uncertainty of using
metformin in heart failure by the clinician may be per-
ceived as damaging to the patient-clinician relationship;
thereby becoming a barrier to patient enrollment[35,36].
Although all clinicians directly involved in our study were
supportive, those outside of the study may not have
believed the research question was of interest or impor-
tance[37]. It is also possible that despite the contraindica-
tion at the time, individual clinicians prescribing for these
patients felt that the benefits outweighed any potential
risks, and may have felt uneasy with the potential with-
Reason for study exclusion Figure 1
Reason for study exclusion.Trials 2009, 10:12 http://www.trialsjournal.com/content/10/1/12
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drawal of metformin therapy. If this is indeed the case,
even if a successful randomized control trial was con-
ducted, one must ask "will it substantially alter prescrib-
ing patterns of the front line clinician?" Numerous
examples exist in the literature where randomized con-
trolled trials have changed the collective thinking of the
scientific community but have failed to make significant
impacts on the prescribing patterns of individual clini-
cians[38].
In addition, as with any clinical trial, the inclusion and
exclusion criteria clearly affected potential enrollment.
We feel, however, few modifications could be made to our
already liberal inclusion criteria, requiring only a physi-
cian diagnosis of heart failure and type 2 diabetes. Previ-
ous metformin use was not an exclusion criteria but
patients receiving high dose metformin therapy (>1500
mg/day) were excluded as it was considered unethical to
potentially randomize patients to placebo for a medica-
tion previously deemed necessary by a physician. Simi-
larly, patients with adequate control of their diabetes (i.e.,
A1c <7%) were also excluded as it was deemed potentially
unsafe to initiate another antidiabetic therapy. With
respect to renal function, the current product monograph
recommends that metformin be avoided in patients with
a creatinine clearance <60 mL/min[6]. In our study, the
criteria was considerably more liberal, allowing patients
with renal function as low as 20–30 mL/min. Of note, the
use of metformin in the setting of chronic kidney disease
with glomerular filtration rates less than 60 ml/min is also
a major contraindication where labeling remains an issue.
Lastly, patients using insulin therapy were excluded. Pre-
vious research has suggested that insulin therapy may be
associated with an increased risk of heart failure[10,39]
and also an increased risk of mortality in people with dia-
betes and heart failure[5,40,41]. We therefore felt it was
important to exclude this treatment to focus on the effects
of metformin. Even if we had not excluded insulin users,
48% of these patients would not have been eligible due to
other exclusions. As a result, changes in the inclusion and
exclusion criteria would likely have not significantly
altered our study outcome.
Conclusion
Our pilot data, coupled with the recent legal and clinical
guideline endorsement for the use of metformin in heart
failure patients, suggest that any future large randomized
controlled trials with metformin in patients with heart
failure and diabetes will be an arduous undertaking.
Given the already frequent and increasing clinical experi-
ence of using metformin in patients with heart failure, a
trial design which limits the use of metformin therapy
may have difficulties in gaining clinician commitment as
clinical uncertainty does not appear to exist[26]. If safety
is still the true concern, it is well known that randomized
controlled trials are, by design, ill suited to address the
issue of safety, especially when rare events are con-
cerned[42,43]. As a result, a large, well designed, phase 4,
prospective evaluation of metformin use in patients with
heart failure may provide the best evidence[42,43].
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